NASDAQ:BOLT Bolt Biotherapeutics Q2 2025 Earnings Report $3.46 -0.12 (-3.35%) Closing price 03:55 PM EasternExtended Trading$3.58 +0.13 (+3.61%) As of 07:30 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. ProfileEarnings HistoryForecast Bolt Biotherapeutics EPS ResultsActual EPS-$4.46Consensus EPS -$6.40Beat/MissBeat by +$1.94One Year Ago EPSN/ABolt Biotherapeutics Revenue ResultsActual Revenue$1.80 millionExpected Revenue$0.82 millionBeat/MissBeat by +$980.00 thousandYoY Revenue GrowthN/ABolt Biotherapeutics Announcement DetailsQuarterQ2 2025Date8/14/2025TimeBefore Market OpensConference Call DateThursday, August 14, 2025Conference Call Time7:00AM ETUpcoming EarningsBolt Biotherapeutics' Q3 2026 earnings is estimated for Wednesday, November 11, 2026, based on past reporting schedules, with a conference call scheduled on Thursday, November 12, 2026 at 4:00 PM ET. Check back for transcripts, audio, and key financial metrics as they become available.Conference Call ResourcesPress Release (8-K)Quarterly Report (10-Q)Earnings HistoryCompany ProfilePowered by Earnings DocumentsPress Release(8-K)Quarterly report(10-Q) Bolt Biotherapeutics Earnings HeadlinesSarah Nemec Sells 4,077 Shares of Bolt Biotherapeutics (NASDAQ:BOLT) StockSeptember 23, 2026 | americanbankingnews.comGrant Yonehiro Sells 4,909 Shares of Bolt Biotherapeutics (NASDAQ:BOLT) StockSeptember 23, 2026 | americanbankingnews.comShould You Convert a Traditional IRA to a Roth After 60?Considering a Roth conversion after 60? The upside includes no income limits on conversions, potential tax-free qualified withdrawals, and no lifetime required minimum distributions. The catch: converting triggers ordinary income tax in the year you convert, and the decision cannot be reversed. The right move depends on your income, tax bracket, and retirement timeline.September 28 at 1:00 AM | SmartAsset (Ad)William Quinn Sells 6,545 Shares of Bolt Biotherapeutics (NASDAQ:BOLT) StockSeptember 23, 2026 | americanbankingnews.comGrant Yonehiro Sells 6,850 Shares of Bolt Biotherapeutics (NASDAQ:BOLT) StockSeptember 23, 2026 | americanbankingnews.comWilliam Quinn Sells 9,132 Shares of Bolt Biotherapeutics (NASDAQ:BOLT) StockSeptember 23, 2026 | americanbankingnews.comSee More Bolt Biotherapeutics Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like Bolt Biotherapeutics? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Bolt Biotherapeutics and other key companies, straight to your email. Email Address About Bolt BiotherapeuticsBolt Biotherapeutics (NASDAQ:BOLT) is a clinical-stage biotechnology company focused on developing immunotherapies for cancer. The company’s platform is designed to stimulate the body’s innate and adaptive immune systems to recognize and attack tumor cells. Bolt’s technology includes Boltbody™ immune-stimulating antibody conjugates, or ISACs. These therapies are intended to combine the targeting capabilities of antibodies with immune-activating components that can recruit and enhance the activity of immune cells within the tumor microenvironment. The company’s development programs have included BDC-1001, an investigational HER2-targeted ISAC for the treatment of HER2-expressing solid tumors, and BDC-3042, an investigational antibody intended to activate macrophages through the Dectin-2 pathway. Bolt is headquartered in Redwood City, California, and has conducted clinical development activities through studies involving patients in the United States and other countries. The company does not currently market an approved commercial product.View Bolt Biotherapeutics ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Latest Articles Brewing Trouble? Starbucks Spills the Beans on 250 Store ClosuresMarketBeat Week in Review – 09/21 - 09/25Analyst Rating Boosts May Signal More Upside for These 3 Stocks3 Stocks Under the Microscope After Large Insider Sales3 Healthcare Stocks Showing Why the Sector Still Has Momentum2 Cybersecurity Stocks Breaking Out as AI Continues to Be a TailwindFertilizer Prices Keep Climbing: 3 Stocks Still Trading at a Discount Upcoming Earnings Micron Technology (9/30/2026)NIKE (10/1/2026)Accenture (10/1/2026)PepsiCo (10/8/2026)Delta Air Lines (10/9/2026)America Movil (10/13/2026)BlackRock (10/13/2026)Citigroup (10/13/2026)The Goldman Sachs Group (10/13/2026)JPMorgan Chase & Co. (10/13/2026) Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
